McDermott + Bull has successfully placed James Hopper as Senior Director, Business Development at TSTrials. Headquartered in Buenos Aires, Argentina, James will execute TSTrials’ global growth strategy, focused on leading business development, fostering existing...
The JPM Q1 2024 MedTech Licensing and Venture report highlights the first quarter of 2024 and shows promising developments in the MedTech investment landscape. There are indications of a potential recovery and growth compared to previous years. Can we be so lucky?...
McDermott + Bull has successfully placed Tom Mock as the Director of Research and Development at NVMedTech. Tom will oversee the completion of one of the company’s main intravascular products, managing its design finalization, initiating GLP animal studies, and...
Healthcare PE activity in Q1 2024 remained subdued, marking a continuation of the downturn seen in 2023. PE sponsors announced or closed an estimated 158 deals in the quarter, maintaining the sluggish pace of 2023. Despite a somewhat more optimistic narrative around...
A few weeks ago, McDermott + Bull Interim Leaders and I hosted a small breakfast for C-Level executives in the life sciences sector. Simon Arkell, CEO and Co-Founder of Ryght AI, joined us as our keynote speaker to share his thoughts and insights on AI and its impact...
McDermott + Bull has successfully placed Kelly Gryschuk as National Director, People and Culture at Pharmasave. Reporting directly to the CEO, Kelly will lead all corporate human resources functions in support of the organization’s mission and vision....
